Zobrazeno 101 - 110
of 178
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Robert H.I. Andtbacka, Axel Hauschild, Eric D. Whitman, Merrick I. Ross, Mark Smithers, Charles R. Scoggins, K. N. Rice, E. A. Wachter, Sanjiv S. Agarwala
Publikováno v:
Annals of Oncology. 27:vi400
Autor:
Jason Chesney, Howard L. Kaufman, Robert H.I. Andtbacka, Mohammed M. Milhem, I. Puzanov, Omid Hamid, Lee D. Cranmer, Merrick I. Ross, Frances A. Collichio, Jenny J. Kim, John A. Glaspy, Lisa Chen, Y. Saenger
Publikováno v:
Annals of Oncology. 27:vi380
Autor:
Jon M. Richards, Brendan D. Curti, Mark Grose, Robert H.I. Andtbacka, Darren R. Shafren, Roberta Karpathy, Mark B. Faries
Publikováno v:
Annals of Oncology. 27:vi360
Autor:
Omid Hamid, David R. Minor, Robert H.I. Andtbacka, Igor Puzanov, Howard L. Kaufman, Mohammed M. Milhem, Ai Li, Ari M. Vanderwalde
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts T-VEC is a herpes simplex virus type-1-derived oncolytic immunotherapy designed to produce GM-CSF and to selectively replicate in and lyse tumors to induce a systemic anti-tumor immune response. A phase 3 study of T-VEC in Stage III
Autor:
Daniel G. Coit, Adil Daud, Christopher K. Bichakjian, Scott K. Pruitt, Susan M. Swetter, Christopher J. Anker, Nicole R. McMillian, William E. Carson, Julie R. Lange, F. Stephen Hodi, Mary C. Martini, Martin D. Fleming, Anthony J. Olszanski, Anne C. Lind, Allan C. Halpern, Nikhil I. Khushalani, Dominick J. DiMaio, Merrick I. Ross, Mark C. Kelley, Maria Ho, Vijay Trisal, Kenneth K. Tanabe, John A. Thompson, Ragini Kudchadkar, Marshall M. Urist, Valerie Guild, Robert H.I. Andtbacka
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 11(4)
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the
Autor:
Eros Lazzerini Denchi, Russell S. Richardson, R. Dirk Noyes, Anthony J. Donato, Lisa A. Lesniewski, Robert H.I. Andtbacka, Richard M. Cawthon, Richard G. Morgan, Stephen J. Ives
Publikováno v:
The FASEB Journal. 27
Autor:
Robert H.I. Andtbacka, Song-Young Park, Stephen J. Ives, Jayson R. Gifford, Russell S. Richardson
Publikováno v:
The FASEB Journal. 27
Autor:
Quan Jiang Zhang, Yan-Ting Shiu, Stephen J. Ives, Ting Ruan, J. David Symons, Robert H.I. Andtbacka, Russell S. Richardson, Sun Hyung Kwon, R. Dirk Noyes
Publikováno v:
Journal of applied physiology (Bethesda, Md. : 1985). 113(11)
Increased local temperature exerts a sympatholytic effect on human skeletal muscle feed arteries. We hypothesized that this attenuated α1-adrenergic receptor responsiveness may be due to a temperature-induced increase in nitric oxide (NO) bioavailab
Publikováno v:
Expert review of anticancer therapy. 12(8)
Extremity soft-tissue sarcomas (ESTS) account for approximately 50% and retroperitoneal soft-tissue sarcomas (RSTS) for approximately 15% of all soft-tissue sarcomas. Surgery remains the main treatment modality for all soft-tissue sarcomas. Neoadjuva
Autor:
Mark Grose, Zipei Peng, Carlo Bifulco, Robert H.I. Andtbacka, Darren R. Shafren, Brendan D. Curti, Christopher Paustian, Sigrun Hallmeyer, Bernard Fox
Publikováno v:
Cancer Research. 76:CT053-CT053
Background: CAVATAK, an oncolytic immunotherapy, is a bio-selected oncolytic strain of Coxsackievirus A21 (CVA21). Following intratumoral (IT) injection, CVA21 preferentially infects ICAM-1 expressing tumor cells, resulting in viral replication, cell